13D Filing: Golden Meditech Holdings Ltd and China Cord Blood Corp (NYSE:NYSE: CO)

 

This Amendment No. 26 is being filed jointly by Golden Meditech Stem Cells (BVI) Company Limited (GM Stem Cells), Golden Meditech Holdings Limited (Golden Meditech), Bio Garden Inc. (Bio Garden), Magnum Opus 3 International Holdings Limited (MO3) and Yuen Kam (Mr. Kam). GM Stem Cells, Golden Meditech, Bio Garden, MO3 and Mr. Kam are collectively referred to as the Reporting Persons.

 

This Amendment No. 26 amends and supplements the statement on Schedule 13D jointly filed with the Securities and Exchange Commission on July 9, 2009 by GM Stem Cells and Golden Meditech, as previously amended and supplemented by amendments to Schedule 13D filed on June 23, 2011, September 30, 2011, April 12, 2012, May 2, 2012, October 4, 2012, July 11, 2013, August 25, 2014, April 27, 2015, May 4, 2015, May 8, 2015, July 27, 2015, August 6, 2015, August 26, 2015, October 26, 2015, November 3, 2015, November 5, 2015, November 13, 2015, November 30, 2015, December 7, 2015, January 7, 2016, September 1, 2016, October 31, 2016, December 30, 2016, April 6, 2017 and April 10, 2017 (as so amended, the Original Schedule 13D). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Original Schedule 13D.

 

Item 4.      Purpose of Transaction

 

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

 

On April 13, 2017, Golden Meditech received a letter from the Issuer regarding the Proposal (the Letter) which provided that, in view of Golden Meditechs proposed sale of its beneficial ownership interest in the Issuer pursuant to the GM New Sale Agreement (the Disposal), Nanjing Ying Pengs future plans regarding the Issuer following the Disposal and the overall viability of the Transaction, the board of directors of the Issuer has resolved to terminate any further evaluation or negotiation of the Transaction.  Golden Meditech therefore will not continue to pursue the Transaction.

 

The description of the Letter herein is not intended to be complete and is qualified in its entirety by reference to the complete text of such document, a copy of which is attached hereto as exhibit 53 and is incorporated by reference in its entirety into this Item 4.

 

Item 7.     Material to be Filed as Exhibits.

 

Item 7 of the Original Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:

 

The following documents are filed as exhibits:

 

Exhibit No.		Description
Exhibit 53		Letter from the Issuer regarding the Proposal, dated as of April 13, 2017.

 

7